AZD6738
Research type
Research Study
Full title
A Phase I, Open-label Study to Assess the Absolute Bioavailability of Ceralasertib (AZD6737) and Absorption, Distribution, Metabolism, and Excretion (ADME) of [14C]-Ceralasertib in Patients with Non-small Cell Lung Cancer, Ovarian Cancer, or Endometrial Cancer
IRAS ID
1010341
Contact name
Neesha Sharma
Contact email
Sponsor organisation
AstraZeneca AB
Clinicaltrials.gov Identifier
Research summary
This study is trying to understand how Ceralasertib, a medication, gets into and leaves the body. This information is important for a few reasons:
It's required by some regulations to know how much of the drug actually enters the bloodstream.
Understanding how the body absorbs the drug can help improve how it's formulated.
Knowing how the drug is eliminated helps predict how it might affect people with kidney or liver problems.
This study can also identify new side effects caused by the drug or its breakdown products.REC name
North East - Newcastle & North Tyneside 1 Research Ethics Committee
REC reference
24/NE/0134
Date of REC Opinion
29 Aug 2024
REC opinion
Further Information Favourable Opinion